PSTV Key Statistics, Chart & Performance
The current stock price of PSTV is 0.5552 USD. In the past month the price decreased by -17.41%. In the past year, price decreased by -52.14%.
PSTV Latest News, Press Relases and Analysis
PSTV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About PSTV
Company Profile
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 21 full-time employees. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Company Info
PLUS THERAPEUTICS INC
4200 Marathon Blvd., Suite 200
Austin TEXAS 78756 US
CEO: Marc. H. Hedrick
Employees: 21
Phone: 17372557194
PLUS THERAPEUTICS INC / PSTV FAQ
What does PSTV do?
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 21 full-time employees. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
What is the stock price of PLUS THERAPEUTICS INC today?
The current stock price of PSTV is 0.5552 USD. The price decreased by -5.11% in the last trading session.
Does PLUS THERAPEUTICS INC pay dividends?
PSTV does not pay a dividend.
What is the ChartMill rating of PLUS THERAPEUTICS INC stock?
PSTV has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in PLUS THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PSTV.
Can you provide the number of employees for PLUS THERAPEUTICS INC?
PLUS THERAPEUTICS INC (PSTV) currently has 21 employees.
PSTV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PSTV. When comparing the yearly performance of all stocks, PSTV is a bad performer in the overall market: 91.69% of all stocks are doing better.
PSTV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PSTV. While PSTV seems to be doing ok healthwise, there are quite some concerns on its profitability.
PSTV Financial Highlights
Over the last trailing twelve months PSTV reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS increased by 32.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.19% | ||
| ROE | -407.06% | ||
| Debt/Equity | 0 |
PSTV Forecast & Estimates
10 analysts have analysed PSTV and the average price target is 7.91 USD. This implies a price increase of 1323.81% is expected in the next year compared to the current price of 0.5552.
For the next year, analysts expect an EPS growth of 90.29% and a revenue growth 7.28% for PSTV